Application of MRI phase-difference mapping to assessment of vascular concentrations of BMS agent in mice

Dynamic contrast-enhanced MRI in mice at high field: estimation of the arterial input function can be achieved by phase imaging

PURPOSE

Quantitative dynamic contrast-enhanced MRI requires an accurate arterial input function (AIF). At high field, increased susceptibility effects and decreased longitudinal relaxivity of contrast agents lead to predominant T2* effects in blood vessels, producing a dip in signal during passage of the contrast agent bolus. This study determined phase-derived AIFs in mice at 11.7 T.

METHODS

AIFs were measured in aorta/vena cava for five FBV/N mice and in iliac arteries/veins for five NMRI mice with a fast low angle shot sequence, simultaneously with tumor imaging (temporal resolution: 1.19 s). Gadoterate was injected into the tail vein as a bolus (0.286 mmol Gd/kg). An in vitro study was also performed to calculate the relationship between ΔΦ and gadolinium concentration.

RESULTS

The phantom system confirmed the linear relationship between measured ΔΦ and gadolinium concentration. In vivo, a dip in arterial magnitude signal made it impossible to quantify the AIF. With phase imaging, a clear quantifiable bolus peak was obtained; peak measured concentration in plasma was 4.9 ± 0.9 mM for FBV/N mice and 8.0 ± 0.6 mM for NMRI mice, close to the expected concentration of 6.8 mM.

CONCLUSION

Phase imaging seems to be an appropriate means to measure the AIF of mice at high field.

Quantification of SPIO nanoparticles in vivo using the finite perturber method

The susceptibility gradients generated by super-paramagnetic iron oxide (SPIO) nanoparticles make them an ideal contrast agent in magnetic resonance imaging. Traditional quantification methods for SPIO nanoparticle-based contrast agents rely on either mapping T₂* values within a region or by modeling the magnetic field inhomogeneities generated by the contrast agent. In this study, a new model-based SPIO quantification method is introduced. The proposed method models magnetic field inhomogeneities by approximating regions containing SPIOs as ensembles of magnetic dipoles, referred to as the finite perturber method. The proposed method was verified using data acquired from a phantom and in vivo mouse models. The phantom consisted of an agar solution with four embedded vials, each vial containing known but different concentrations of SPIO nanoparticles. Gaussian noise was also added to the phantom data to test performance of the proposed method. The in vivo dataset was acquired using five mice, each of which was subcutaneously implanted in the flanks with 1 × 10(5) labeled and 1 × 10(6) unlabeled C6 glioma cells. For the phantom data set, the proposed algorithm was generate accurate estimations of the concentration of SPIOs. For the in vivo dataset, the method was able to give estimations of the concentration within SPIO-labeled tumors that are reasonably close to the known concentration.

Real-time 3D MRI of contrast agents in whole living mice

A specific mouse whole body coil and a dedicated gradient system at 4.7 T were coupled with an ultra-fast 3D gradient echo MRI and keyhole reconstruction technique to obtain 3D whole-body dynamic T(1)-weighted or T(2)*-weighted imaging. The technique was used to visualize the real-time distribution of non-targeting T(1) and T(2)* contrast agent (CA) in a glioma-bearing mouse model. T(1) dynamic contrast-enhancement imaging was performed with a fast imaging with steady-state precession sequence [echo time/repetition time (TE/TR), 1.32/3.7 ms] before and after CA injection (Gd-DOTA and BSA-Gd-DOTA) for 21 min. The temporal resolution was 1 image/6.5 s. T(2)* imaging (TE/TR, 4/8 ms) was performed before and after iron-based (small and ultra-small particles of iron oxide) CA injection for 45 min. The temporal resolution was 1 image/14 s. Signal-to-noise ratio curves were determined in various mouse organs. The whole-body coil and gradient systems made it possible to acquire data with sufficient and homogeneous signal-to-noise ratio on the whole animal. The spatial resolution allowed adequate depiction of the major organs, blood vessels and brain glioma. The distribution and the time-course of T(1) and T(2)* contrasts upon contrast agent injection were also assessed. 3D whole-body mouse MRI is feasible at high spatial resolution in movie mode and can be applied successfully to visualize real-time contrast agent distribution. This method should be effective in future preclinical molecular imaging studies.

Determination of the venous output function from MR signal phase: feasibility for quantitative DCE-MRI in human brain

For dynamic contrast-enhanced MRI studies in the human brain, it is useful to measure the venous output function (VOF). The purpose of this work was to explore the feasibility of measuring the VOF using the MR signal phase (in absolute units of gadolinium concentration) in the superior sagittal sinus. Phantom experiments were performed to validate the technique for different superior sagittal sinus angles (theta = 0-48 degrees relative to the main magnetic field), different curvatures (straight or radius = 45 mm), and different spatial resolutions (2.2-5.5 mm, to study partial-volume effects). Additionally, the technique was tested on three patients. The phantom experimental results (echo time = 5.5 ms, theta <or= 21 degrees) agreed with theoretical predictions to within 10%. For the patient studies, the measured VOFs had reasonable amplitude and shape characteristics and the patients' superior sagittal sinus angles (<15 degrees) and curvatures (radii approximately 40 mm) were within the range explored with phantoms. Our results suggest that partial-volume contributions to the VOF will be <5% and that the VOF can be evaluated in vivo to within 10% error. In conclusion, it is highly feasible to use MR signal phase to measure the VOF in the superior sagittal sinus for human dynamic contrast-enhanced MRI.